SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma’s arm gets USFDA’s approval for Sevelamer Hydrochloride Tablets

12 Jul 2023 Evaluate

Aurobindo Pharma’s wholly owned subsidiary company -- APL Healthcare has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sevelamer Hydrochloride Tablets 400 mg and 800 mg, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation. 

The approved product has an estimated market size of around $37 million for the twelve months ending May 2023, according to IQVIA. This is the 57th ANDA approved out of APL Healthcare Unit IV formulation facility, used for manufacturing oral products. 

Aurobindo now has a total of 463 ANDA approvals (437 Final approvals and 26 tentative approvals) from USFDA. Sevelamer Hydrochloride Tablets 400 mg and 800 mg is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×